Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 294

1.

RELATIONSHIPS BETWEEN PERITONEAL PROTEIN CLEARANCE AND PARAMETERS OF FLUID STATUS AGREE WITH CLINICAL OBSERVATIONS IN OTHER DISEASES THAT VENOUS CONGESTION INCREASES MICROVASCULAR PROTEIN ESCAPE.

Krediet RT, Yoowannakul S, Harris LS, Davenport A.

Perit Dial Int. 2019 Jan 18. pii: pdi.2018.00016. doi: 10.3747/pdi.2018.00016. [Epub ahead of print]

PMID:
30661003
2.

Peritoneal Protein Losses Depend on More Than Just Peritoneal Dialysis Modality and Peritoneal Membrane Transporter Status.

Yoowannakul S, Harris LS, Davenport A.

Ther Apher Dial. 2018 Apr;22(2):171-177. doi: 10.1111/1744-9987.12647. Epub 2018 Jan 4.

PMID:
29314721
3.

Conservative management of migrated percutaneous endoscopic colostomy tube.

Chase TJ, Luck J, Harris LS, Bashir G.

J Surg Case Rep. 2017 Jan 6;2017(1). pii: rjw227. doi: 10.1093/jscr/rjw227.

4.

Suboptimal identification of patient-specific risk factors for poor wound healing can be improved by simple interventions.

Harris LS, Luck JE, Atherton RR.

Int Wound J. 2017 Feb;14(1):138-141. doi: 10.1111/iwj.12573. Epub 2016 Mar 22.

PMID:
27000636
5.

Coping style and memory specificity in adolescents and adults with histories of child sexual abuse.

Harris LS, Block SD, Ogle CM, Goodman GS, Augusti EM, Larson RP, Culver MA, Pineda AR, Timmer SG, Urquiza A.

Memory. 2016 Sep;24(8):1078-90. doi: 10.1080/09658211.2015.1068812. Epub 2015 Aug 4.

PMID:
26241375
6.

Child maltreatment, trauma-related psychopathology, and eyewitness memory in children and adolescents.

McWilliams K, Harris LS, Goodman GS.

Behav Sci Law. 2014 Nov-Dec;32(6):702-17. doi: 10.1002/bsl.2143.

PMID:
25537437
7.

Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor.

Ben Haddou T, Malfacini D, Calo G, Aceto MD, Harris LS, Traynor JR, Coop A, Schmidhammer H, Spetea M.

Mol Pain. 2014 Jul 24;10:48. doi: 10.1186/1744-8069-10-48.

8.

Bowel hath no fury like a gallbladder inflamed.

Khan A, Flavin KE, Harris LS, Chaudhry MN, Reading N.

J Surg Case Rep. 2014 Apr 22;2014(4). pii: rju028. doi: 10.1093/jscr/rju028. Print 2014 Apr.

9.

Intimate partner violence and children's memory.

Gustafsson HC, Coffman JL, Harris LS, Langley HA, Ornstein PA, Cox MJ.

J Fam Psychol. 2013 Dec;27(6):937-44. doi: 10.1037/a0034592. Epub 2013 Nov 4.

10.

Autobiographical memory specificity in child sexual abuse victims.

Ogle CM, Block SD, Harris LS, Goodman GS, Pineda A, Timmer S, Urquiza A, Saywitz KJ.

Dev Psychopathol. 2013 May;25(2):321-32. doi: 10.1017/S0954579412001083.

11.

Fumaroylamino-4,5-epoxymorphinans and related opioids with irreversible μ opioid receptor antagonist effects.

Moynihan HA, Derrick I, Broadbear JH, Greedy BM, Aceto MD, Harris LS, Purington LC, Thomas MP, Woods JH, Traynor JR, Husbands SM, Lewis JW.

J Med Chem. 2012 Nov 26;55(22):9868-74. doi: 10.1021/jm301096s. Epub 2012 Oct 31.

12.

l-theanine attenuates abstinence signs in morphine-dependent rhesus monkeys and elicits anxiolytic-like activity in mice.

Wise LE, Premaratne ID, Gamage TF, Lichtman AH, Hughes LD, Harris LS, Aceto MD.

Pharmacol Biochem Behav. 2012 Dec;103(2):245-52. doi: 10.1016/j.pbb.2012.08.008. Epub 2012 Aug 23.

13.

Effects of the specific α4β2 nAChR antagonist, 2-fluoro-3-(4-nitrophenyl) deschloroepibatidine, on nicotine reward-related behaviors in rats and mice.

Tobey KM, Walentiny DM, Wiley JL, Carroll FI, Damaj MI, Azar MR, Koob GF, George O, Harris LS, Vann RE.

Psychopharmacology (Berl). 2012 Sep;223(2):159-68. doi: 10.1007/s00213-012-2703-3. Epub 2012 Apr 22.

14.

MDAN-21: A Bivalent Opioid Ligand Containing mu-Agonist and Delta-Antagonist Pharmacophores and Its Effects in Rhesus Monkeys.

Aceto MD, Harris LS, Negus SS, Banks ML, Hughes LD, Akgün E, Portoghese PS.

Int J Med Chem. 2012;2012:327257. doi: 10.1155/2012/327257. Epub 2012 Apr 29.

15.

False memory for trauma-related Deese-Roediger-McDermott lists in adolescents and adults with histories of child sexual abuse.

Goodman GS, Ogle CM, Block SD, Harris LS, Larson RP, Augusti EM, Cho YI, Beber J, Timmer S, Urquiza A.

Dev Psychopathol. 2011 May;23(2):423-38. doi: 10.1017/S0954579411000150.

16.

Removal of continuous nicotine infusion produces somatic but not behavioral signs of withdrawal in mice.

Kwilasz AJ, Harris LS, Vann RE.

Pharmacol Biochem Behav. 2009 Nov;94(1):114-8. doi: 10.1016/j.pbb.2009.07.015. Epub 2009 Aug 4.

17.

Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.

Cami-Kobeci G, Neal AP, Bradbury FA, Purington LC, Aceto MD, Harris LS, Lewis JW, Traynor JR, Husbands SM.

J Med Chem. 2009 Mar 26;52(6):1546-52. doi: 10.1021/jm8015552.

18.

The influence of esters and carboxylic acids as the N-substituent of opioids. Part 1: Benzomorphans.

Metcalf MD, Aceto MD, Harris LS, Woods JH, Traynor JR, Coop A, May EL.

Bioorg Med Chem. 2008 Jan 15;16(2):869-73. Epub 2007 Oct 13.

19.

Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.

Hiebel AC, Lee YS, Bilsky E, Giuvelis D, Deschamps JR, Parrish DA, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Partilla JS, Rothman RB, Cheng K, Jacobson AE, Rice KC.

J Med Chem. 2007 Aug 9;50(16):3765-76. Epub 2007 Jul 11.

PMID:
17625813
20.

NIH 11082 produces anti-depressant-like activity in the mouse tail-suspension test through a delta-opioid receptor mechanism of action.

Naidu PS, Lichtman AH, Archer CC, May EL, Harris LS, Aceto MD.

Eur J Pharmacol. 2007 Jul 2;566(1-3):132-6. Epub 2007 Mar 30.

21.
22.

Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists.

Cheng K, Kim IJ, Lee MJ, Adah SA, Raymond TJ, Bilsky EJ, Aceto MD, May EL, Harris LS, Coop A, Dersch CM, Rothman RB, Jacobson AE, Rice KC.

Org Biomol Chem. 2007 Apr 21;5(8):1177-90. Epub 2007 Mar 1.

PMID:
17406716
23.

Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.

Kushner DM, Connor JP, Sanchez F, Volk M, Schink JC, Bailey HH, Harris LS, Stewart SL, Fine J, Hartenbach EM; Wisconsin Oncology Network.

Gynecol Oncol. 2007 May;105(2):358-64. Epub 2007 Jan 29.

PMID:
17258800
24.

Exempt preparations: Historical perspectives.

Harris LS.

Drug Alcohol Depend. 2006 Jun;83 Suppl 1:S48-51. Epub 2006 Mar 10. Review.

PMID:
16529881
25.
26.

Effect of a 6-cyano substituent in 14-oxygenated N-methylmorphinans on opioid receptor binding and antinociceptive potency.

Spetea M, Greiner E, Aceto MD, Harris LS, Coop A, Schmidhammer H.

J Med Chem. 2005 Jul 28;48(15):5052-5.

PMID:
16033285
27.

Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.

Carroll I, Thomas JB, Dykstra LA, Granger AL, Allen RM, Howard JL, Pollard GT, Aceto MD, Harris LS.

Eur J Pharmacol. 2004 Oct 6;501(1-3):111-9.

PMID:
15464069
28.

Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys.

Beardsley PM, Aceto MD, Cook CD, Bowman ER, Newman JL, Harris LS.

Exp Clin Psychopharmacol. 2004 Aug;12(3):163-72.

PMID:
15301633
29.

Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.

Spetea M, Schüllner F, Moisa RC, Berzetei-Gurske IP, Schraml B, Dörfler C, Aceto MD, Harris LS, Coop A, Schmidhammer H.

J Med Chem. 2004 Jun 3;47(12):3242-7.

PMID:
15163203
30.

Synthesis and biological evaluation of 14-alkoxymorphinans. 20. 14-phenylpropoxymetopon: an extremely powerful analgesic.

Schütz J, Spetea M, Koch M, Aceto MD, Harris LS, Coop A, Schmidhammer H.

J Med Chem. 2003 Sep 11;46(19):4182-7.

PMID:
12954070
31.

Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.

Greiner E, Spetea M, Krassnig R, Schüllner F, Aceto M, Harris LS, Traynor JR, Woods JH, Coop A, Schmidhammer H.

J Med Chem. 2003 Apr 24;46(9):1758-63.

PMID:
12699394
32.

N-(trifluoromethyl)benzyl substituted N-normetazocines and N-norketobemidones.

May EL, Coop A, Woods JH, Aceto MD, Bowman ER, Harris LS, Traynor JR.

Bioorg Med Chem. 2003 Jan 2;11(1):31-3.

PMID:
12467704
33.

A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.

Bailey HH, Levy D, Harris LS, Schink JC, Foss F, Beatty P, Wadler S.

Gynecol Oncol. 2002 Jun;85(3):464-8.

PMID:
12051875
34.

Drug dependence studies and regulations: an overview of the past and present.

Harris LS.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2001 Nov;21(5):171-4. No abstract available.

PMID:
11797422
35.
36.

Behavioral effects of flunitrazepam: reinforcing and discriminative stimulus effects in rhesus monkeys and prevention of withdrawal signs in pentobarbital-dependent rats.

Gerak LR, Woolverton WL, Nader MA, Patrick GA, Harris LS, Winger G, Woods JH, France CP.

Drug Alcohol Depend. 2001 Jun 1;63(1):39-49.

PMID:
11297830
37.

Radiologic removal of buried gastrostomy bumpers in pediatric patients.

Crowley JJ, Vora D, Becker CJ, Harris LS.

AJR Am J Roentgenol. 2001 Mar;176(3):766-8. No abstract available.

PMID:
11222222
38.

Synthesis and in vitro and in vivo activity of (-)-(1R,5R,9R)- and (+)-(1S,5S,9S)-N-alkenyl-, -N-alkynyl-, and -N-cyanoalkyl-5, 9-dimethyl-2'-hydroxy-6,7-benzomorphan homologues.

May EL, Jacobson AE, Mattson MV, Traynor JR, Woods JH, Harris LS, Bowman ER, Aceto MD.

J Med Chem. 2000 Dec 28;43(26):5030-6.

PMID:
11150174
39.

N-Cyclohexylethyl-N-noroxymorphindole: a mu-opioid preferring analogue of naltrindole.

Coop A, Jacobson AE, Aceto MD, Harris LS, Traynor JR, Woods JH, Rice KC.

Bioorg Med Chem Lett. 2000 Nov 6;10(21):2449-51.

PMID:
11078198
40.

Dihydroetorphine: physical dependence and stereotypy after continuous infusion in the rat.

Aceto MD, Scates SM, Harris LS, Ji Z.

Eur J Pharmacol. 2000 Jan 3;387(1):31-7.

PMID:
10633157
41.

Paclitaxel, carboplatin, and hexamethyl-melamine (taxchex) as first-line therapy for ovarian cancer.

Hartenbach EM, Harris LS, Bailey HH, Grosen EA, Larrison E, Chen D, Twiggs LB, Schink JC.

Cancer J Sci Am. 1999 Nov-Dec;5(6):348-55.

PMID:
10606476
42.

Stereoselective mu- and delta-opioid receptor-related antinociception and binding with (+)-thebaine.

Aceto MD, Harris LS, Abood ME, Rice KC.

Eur J Pharmacol. 1999 Jan 22;365(2-3):143-7.

PMID:
9988096
43.

Anti-allodynic actions of intravenous opioids in the nerve injured rat: potential utility of heroin and dihydroetorphine against neuropathic pain.

Martin TJ, Hairston CT, Lutz PO, Harris LS, Porreca F.

Eur J Pharmacol. 1998 Sep 11;357(1):25-32.

PMID:
9788770
44.

3-Alkyl ethers of clocinnamox: delayed long-term mu-antagonists with variable mu efficacy.

Husbands SM, Sadd J, Broadbear JH, Woods JH, Martin J, Traynor JR, Aceto MD, Bowman ER, Harris LS, Lewis JW.

J Med Chem. 1998 Aug 27;41(18):3493-8.

PMID:
9719602
45.

Dependence studies of new compounds in the rhesus monkey, rat and mouse (1997).

Aceto MD, Bowman ER, Harris LS, May EL.

NIDA Res Monogr. 1998 Mar;178:363-407. No abstract available.

PMID:
9686404
46.

Radiologic placement of long-term subcutaneous venous access ports in children.

Crowley JJ, Pereira JK, Harris LS, Becker CJ.

AJR Am J Roentgenol. 1998 Jul;171(1):257-60.

PMID:
9648800
47.

Etorphines: mu-opioid receptor-selective antinociception and low physical dependence capacity.

Aceto MD, Harris LS, Bowman ER.

Eur J Pharmacol. 1997 Nov 12;338(3):215-23.

PMID:
9424015
48.

A killing of Baby Doe.

Harris LS.

J Forensic Sci. 1997 Nov;42(6):1180-2.

PMID:
9397566
49.

Automobile hood ornament as penetrating missile.

Harris LS.

N C Med J. 1997 Nov-Dec;58(6):458-60. No abstract available.

PMID:
9392963
50.

Evaluation of the discriminative stimulus and reinforcing effects of dihydroetorphine.

Beardsley PM, Harris LS.

Drug Alcohol Depend. 1997 Nov 25;48(2):77-84.

PMID:
9363406

Supplemental Content

Loading ...
Support Center